How effective is Risankizumab?

Risankizumab/Risankizumab (CD) has shown significant effects in the treatment of a variety of immune-mediated diseases, especially in clinical studies in the fields of psoriasis, psoriatic arthritis (PA), ulcerative colitis, Crohn's disease (CD).

In studies of plaque psoriasis,Skyrizi has shown significant efficacy in patients with moderate to severe disease. Four major studies involving more than 2,100 patients showed that Skyrizi was significantly better than placebo and other comparators in improving symptoms. In the first two studies, approximately 75% of patients treated with Skyrizi experienced a greater than 90% decrease in PASI scores within 16 weeks, compared with 45% of patients treated with ustekinumab and 4% of patients treated with placebo. In addition, Skyrizi patients maintained symptom improvement after 52 weeks of continued treatment.

Two major studies in psoriatic arthritis show that Skyrizi is equally effective. In the first study, of 443 patients who had failed to respond to DMARDs or biologic drugs, after 24 weeks of treatment, 51% of patients who received Skyrizi experienced a reduction of more than 20% in symptoms, compared with 27% of those who received a placebo. The results of the second study showed that among 964 patients, 57% of the patients in the Skyrizi group experienced significant improvement in symptoms, compared with only 34% of the placebo group.

In Crohn's disease,Skyrizi's efficacy continues to attract attention. The first of two studies involving 1,549 patients showed a clinical response rate of 35% after 12 weeks in patients who received Skyrizi, compared with 19% in the placebo group. The second study further confirmed that 44% of patients who received Skyrizi achieved clinical remission after 12 weeks.

Finally, in the ulcerative colitis study, 977 patients participated in a major study that showed that after 12 weeks of treatment, 20% of patients taking Skyrizi achieved clinical remission, compared with only 6% of the placebo group. Another long-term follow-up study showed that after 52 weeks of treatment, 40% of low-dose and 38% of high-dose patients achieved clinical remission, compared with only 25% of the placebo group.

Reference materials:https://go.drugbank.com/drugs/DB14762